Table 4.
Prevalence of diabetes treatments and glycemic control in adults with diabetes across years of enrollment (based on survey completion year)
| Proportion (%) | Total (N = 81,332) | 20181 (N = 43,568) | 2019 (N = 26,142) | 2020 (N = 6336) | 2021 (N = 5291) |
|---|---|---|---|---|---|
| Any DM medication | 63.3% | 63.6% | 63.9% | 61.8% | 59.9%* |
| SGLT2-i or GLP-1 RA | 13.5% | 13.5% | 13.4% | 14.3% | 13.5%† |
| SGLT2-i and GLP-1 RA | 3.1% | 3.1% | 3.2% | 2.9% | 3.1% |
| GLP-1 RA | 10.3% | 10.3% | 10.2% | 10.9% | 10.4%† |
| SGLT2-i | 6.3% | 6.3% | 6.4% | 6.3% | 6.2%† |
| Insulin use | 38.9% | 39.6% | 38.8% | 36.8% | 36.0%* |
| Metformin | 36.2% | 36.5% | 36.7% | 34.1% | 32.8%* |
| Dipeptidyl peptidase 4 (DPP4) | 6.8% | 7.0% | 6.9% | 6.0% | 5.6%* |
| HbA1c categories | |||||
| < 7% | 72.0% | 71.5% | 73.0% | 71.7% | 71.3%* |
| 7–8% | 11.9% | 11.9% | 11.7% | 13.3% | 12.3% |
| ≥ 8% | 16.1% | 16.6% | 15.4% | 15.0% | 16.4% |
1Also includes patients with completed survey information from earlier years
†p value < 0.05, *p < .001 across groups